Reshma Kewalramani - Vertex Pharmaceuticals President
| VRTX Stock | MXN 8,150 42.60 0.53% |
President
Dr. Reshma Kewalramani, M.D. is an Executive Vice President Global Medicines Development and Medical Affairs, Chief Medical Officer of the Company since April 1, 2018. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017 she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President Global Clinical Development, Nephrology Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. Dr. Kewalramani is the industry representative to the FDAs Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Womens Hospital combined program since 2020.
| Age | 45 |
| Tenure | 4 years |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Heidi Capozzi | The Boeing | 49 | |
| Brett Gerry | The Boeing | 47 | |
| Andrew Iaboni | McEwen Mining | 41 | |
| Susan Doniz | The Boeing | 49 | |
| Michelle Browdy | International Business Machines | 58 | |
| Jenette Ramos | The Boeing | 53 | |
| Andrew Cecere | US Bancorp | 62 | |
| Diana Sands | The Boeing | 53 | |
| Thomas Rosamilia | International Business Machines | 62 | |
| BertrandMarc Allen | The Boeing | 45 | |
| Isaac Joseph | NOV Inc | 66 | |
| Joseph Rovig | NOV Inc | 62 | |
| James Chosy | US Bancorp | 59 | |
| Gregory Hyslop | The Boeing | 60 | |
| Arvind Krishna | International Business Machines | 60 | |
| Katherine Quinn | US Bancorp | 58 | |
| Patricia Murphy | International Business Machines | N/A | |
| Timothy Keating | The Boeing | 57 | |
| Catalina Almeida | Bolsa Mexicana de | N/A | |
| James Kavanaugh | International Business Machines | 56 | |
| Hugo Pliego | Bolsa Mexicana de | 63 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | ||
| Michael Parini, Executive Vice President, Chief Legal and Administrative Officer | ||
| Alan Garber, Independent Director | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Ex Chairman | ||
| MD FASN, Pres CEO | ||
| Stuart BSc, Ex COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Diana McKenzie, Independent Director | ||
| Sangeeta Bhatia, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Nia Tatsis, Senior Vice President Chief Regulatory Officer | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Corporate Controller | ||
| David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | ||
| Amit Sachdev, Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO | ||
| Charles Wagner, Chief Financial Officer, Executive Vice President | ||
| Gerald Bruce, Executive Vice President Commercial Operations | ||
| Ourania Tatsis, Ex Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, VP Relations | ||
| Lloyd Carney, Independent Director | ||
| Yuchun Lee, Independent Director | ||
| Stuart Arbuckle, Executive Vice President Chief Commercial Officer | ||
| Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | ||
| Jeffrey Leiden, Chairman of the Board, President, Chief Executive Officer |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 1.41 T | |||
| Shares Outstanding | 257.09 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 96.96 % | |||
| Price To Earning | 17.50 X | |||
| Price To Book | 6.07 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.